Medifast Inc (NYSE:MED – Get Free Report) Director Daniel Chard sold 9,544 shares of the business’s stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $11.73, for a total transaction of $111,951.12. Following the transaction, the director directly owned 130,609 shares in the company, valued at approximately $1,532,043.57. The trade was a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Medifast Stock Performance
Shares of MED stock traded down $0.09 on Wednesday, hitting $11.53. The stock had a trading volume of 138,133 shares, compared to its average volume of 113,400. The stock’s 50 day moving average is $11.67 and its 200-day moving average is $11.34. The firm has a market capitalization of $128.85 million, a price-to-earnings ratio of -4.95 and a beta of 0.71. Medifast Inc has a 52-week low of $9.22 and a 52-week high of $14.15.
Medifast (NYSE:MED – Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.37. Medifast had a negative net margin of 8.08% and a negative return on equity of 6.69%. The firm had revenue of $76.38 million for the quarter, compared to the consensus estimate of $72.70 million. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. Equities analysts expect that Medifast Inc will post -1.04 earnings per share for the current year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
MED has been the topic of a number of analyst reports. Weiss Ratings raised Medifast from a “sell (e+)” rating to a “sell (d)” rating in a research report on Monday, August 17th. Zacks Research downgraded Medifast from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Medifast currently has an average rating of “Reduce” and a consensus target price of $12.00.
Get Our Latest Stock Analysis on Medifast
Medifast Company Profile
Medifast, Inc (NYSE: MED) is a health and wellness company that provides weight-management and healthy-lifestyle products and programs. Its principal brand is OPTAVIA, which offers structured plans designed to support weight loss, nutrition, and long-term habit development.
The company’s product portfolio includes meal-replacement shakes, bars, snacks, entrees, beverages, supplements, and other packaged “Fuelings.” Medifast also supports customers through independent OPTAVIA Coaches, who provide guidance, accountability, and lifestyle support through the company’s direct-selling model.
Founded in 1980, Medifast serves customers primarily in the United States through its e-commerce and direct-to-consumer channels.
Further Reading
- Five stocks we like better than Medifast
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
- O’Reilly Automotive’s Stock Slump Hides a Stronger Business
- McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
- Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.
